Document is current
Any future updates will be listed below
-
Authors
Fang, Andrew
Tang, Xinli
Fleming, Madeleine
Tancowny, Brian
Wang, Xiongyao
Wang, YongLiang
Daude, Nathalie
Dorosh, Lyudmyla
Fleck, Shelaine C.
Rathod, Vineet
Coustou, Virginie
Cervantes, Silvia A.
Velásquez, Camilo Duque
Westaway, David
Aiken, Judd
McKenzie, Debbie
Telling, Glenn
Stepanova, Maria
Saupe, Sven J.
Siemer, Ansgar B.
Wille, Holger
-
Funding
Funding for this research was provided by:
Alberta Prion Research Institute (201600023)
Alberta Prion Research Institute (20160012)
Canada Foundation for Innovation (39588)
Alberta Environment and Protected Areas (24GRLND130)
Natural Sciences and Engineering Research Council of Canada (ALLRP 571218-21)
National Institutes of Health (P01AI077774)
National Institutes of Health (R01 NS133820)
National Institutes of Health (R01 AI156037)
Alberta Conservation Association (030-00-90-320)
Alberta Innovates (212200469)
Creutzfeldt-Jakob Disease Foundation (Katie Dopirak Memorial Grant)
Results Driven Agriculture Research (2025T3838R)
Alberta Ministry of Technology and Innovation (SPP-ARC (Striving for Pandemic Preparedness - The Alberta Research Consortium))
- License Information
-
More Information
Article History
Received: 5 March 2026
Revised: 20 March 2026
Accepted: 7 April 2026
First Online: 17 April 2026
Declarations
:
: AF, XT, VR, and HW were awarded a US patent No. 12,098,173, titled ‘Innocuous, structured scaffolds for structure-based amyloid disease vaccines and antigens’, which covers, in part, the inventions described in this publication. Similar patent applications are pending in Canada, the European Union, Japan and Hong Kong. HW is a co-founder of Solenoid Biosciences LLC, which will attempt to commercialize structure-based vaccines for Alzheimer’s and Parkinson’s disease. The remaining authors declare that they have no competing interests.
: All animal experiments were performed in accordance with the ethics guidelines from the University of Alberta Animal Care and Use Committee (ACUC) according to guidelines from the Canadian Council on Animal Care (CCAC). The research protocols of this study were approved under AUP00002852, titled “Vaccines for neurodegenerative diseases”, AUP00000884, titled “Structural biology of infectious mammalian prions”, and AUP00000424, titled “Production of antibodies for neurodegenerative disease research”.
